Support Your Metabolism with Clinically-Studied Ingredients

Mitolyn — 6 plant-based nutrients to boost mitochondrial health, energy & natural fat burning.

★★★★★ 127,000+ customers · 90-day money-back guarantee

Dr. Joseph Dellinger, MD

Internal Medicine Pasadena, CA Male

NPI: 1740691377

Total Payments

$77,175

2024 Payments

$18,898

Companies

Transactions

Medicare Patients

962

Medicare Billing

$164,915

Payment Breakdown by Category

Consulting$50,526 (65.5%)

Research$25,660 (33.2%)

Food & Beverage$989.47 (1.3%)

Other$0.00 (0.0%)

Payments by Nature

Nature of Payment	Amount	Transactions	Share
Consulting Fee	$50,526	64	65.5%
Unspecified	$25,660	13	33.2%
Food and Beverage	$989.47	16	1.3%

Payments by Type

General

$51,516

80 transactions

Research

$25,660

13 transactions

Top Paying Companies

Company	Total	Records	Latest Year
AstraZeneca UK Limited	$35,706	45	$0 (2024)
Novartis Pharmaceuticals Corporation	$18,732	8	$0 (2024)
Eisai Inc.	$6,342	7	$0 (2024)
AstraZeneca AB	$4,604	6	$0 (2021)
UCB Biosciences Inc.	$3,556	2	$0 (2023)
BIOVERATIV THERAPEUTICS INC.	$1,625	4	$0 (2020)
SANOFI US SERVICES INC.	$1,500	1	$0 (2019)
Regeneron Pharmaceuticals, Inc.	$1,360	2	$0 (2023)
UCB SA	$1,063	1	$0 (2022)
Eli Lilly and Company	$1,062	1	$0 (2022)

Payment History by Year

Year	Amount	Transactions	Top Company
2024	$18,898	21	AstraZeneca UK Limited ($15,215)
2023	$14,174	9	Novartis Pharmaceuticals Corporation ($8,670)
2022	$19,455	16	AstraZeneca UK Limited ($8,251)
2021	$16,682	21	AstraZeneca UK Limited ($8,025)
2020	$5,625	10	AstraZeneca UK Limited ($1,750)
2019	$1,500	1	SANOFI US SERVICES INC. ($1,500)
2018	$329.15	5	E.R. Squibb & Sons, L.L.C. ($179.90)
2017	$511.25	10	E.R. Squibb & Sons, L.L.C. ($159.14)

All Payment Transactions

93 individual payment records from CMS Open Payments — Page 4 of 4

Date	Company	Product	Nature	Form	Amount	Type
01/23/2020	AstraZeneca UK Limited	—	Consulting Fee	Cash or cash equivalent	$125.00	General
01/23/2020	BIOVERATIV THERAPEUTICS INC.	—	Consulting Fee	Cash or cash equivalent	$125.00	General
12/26/2019	SANOFI US SERVICES INC.	BIVV020 (Drug)	Consulting Fee	Cash or cash equivalent	$1,500.00	General
11/01/2018	E.R. Squibb & Sons, L.L.C.	ELIQUIS (Drug)	Food and Beverage	Cash or cash equivalent	$116.63	General
Category: Cardiovascular
10/09/2018	Amgen Inc.	Aimovig (Biological)	Food and Beverage	In-kind items and services	$117.92	General
Category: Neuroscience
06/26/2018	E.R. Squibb & Sons, L.L.C.	ELIQUIS (Drug)	Food and Beverage	Cash or cash equivalent	$63.27	General
Category: Cardiovascular
06/26/2018	PFIZER INC.	ELIQUIS (Drug)	Food and Beverage	In-kind items and services	$14.66	General
Category: CARDIOVASCULAR;METABOLIC DISEASE
03/01/2018	Novo Nordisk Inc	Victoza (Drug), Tresiba, Xultophy 100/3.6	Food and Beverage	In-kind items and services	$16.67	General
Category: Diabetes
12/14/2017	E.R. Squibb & Sons, L.L.C.	ELIQUIS (Drug)	Food and Beverage	Cash or cash equivalent	$104.04	General
Category: Cardiovascular
12/05/2017	PFIZER INC.	ELIQUIS (Drug)	Food and Beverage	In-kind items and services	$14.11	General
Category: CARDIOVASCULAR;METABOLIC DISEASE
11/16/2017	E.R. Squibb & Sons, L.L.C.	ELIQUIS (Drug)	Food and Beverage	Cash or cash equivalent	$19.39	General
Category: Cardiovascular
10/05/2017	E.R. Squibb & Sons, L.L.C.	ELIQUIS (Drug)	Food and Beverage	Cash or cash equivalent	$14.70	General
Category: Cardiovascular
08/16/2017	PFIZER INC.	ELIQUIS (Drug)	Food and Beverage	In-kind items and services	$13.94	General
Category: CARDIOVASCULAR;METABOLIC DISEASE
08/16/2017	E.R. Squibb & Sons, L.L.C.	ELIQUIS (Drug)	Food and Beverage	Cash or cash equivalent	$7.51	General
Category: Cardiovascular
08/15/2017	Novartis Pharmaceuticals Corporation	COSENTYX (Biological)	Food and Beverage	In-kind items and services	$112.80	General
Category: DERMATOLOGY
07/27/2017	Otsuka America Pharmaceutical, Inc.	SAMSCA (Drug)	Food and Beverage	In-kind items and services	$114.40	General
Category: NEPHROLOGY
04/06/2017	E.R. Squibb & Sons, L.L.C.	ELIQUIS (Drug)	Food and Beverage	Cash or cash equivalent	$13.50	General
Category: Cardiovascular
02/09/2017	Genentech USA, Inc.	TECENTRIQ (Biological)	Food and Beverage	In-kind items and services	$96.86	General
Category: BioOncology

«1 2 3 4

Research Studies & Clinical Trials

Study Name	Company	Amount	Records
A first-in-human, randomized, participant- and investigator-blinded, placebo-controlled, two-part, single ascending intravenous dose study, to assess the safety, tolerability, and pharmacokinetics of VHB937 in healthy non-Japanese and Japanese adults	Novartis Pharmaceuticals Corporation	$7,990	1
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B)	UCB Biosciences Inc.	$3,556	2
A 3-PART FIRST-IN-HUMAN STUDY CONSISTING OF RANDOMIZED, DOUBLE-BLINDED, PLACEBOCONTROLLED, SINGLE AND MULTIPLE ASCENDING ORAL DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RHH646, AND A RANDOMIZED, OPEN-LABEL	Novartis Pharmaceuticals Corporation	$3,008	1
A FIRST-IN-HUMAN, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR-BLINDED, PLACEBO-CONTROLLED, TWO-PART, SINGLE ASCENDING INTRAVENOUS DOSE STUDY, TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF VHB937 IN HEALTHY NON-JAPANESE AND JAPANESE ADULTS	Novartis Pharmaceuticals Corporation	$2,196	1
A FIRST-IN-HUMAN, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR-BLINDED, PLACEBO CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF XEP527 IN HEALTHY PARTICIPANTS	Novartis Pharmaceuticals Corporation	$1,850	1
A first-in-human, randomized, participant and investigator blinded, placebo-controlled, single ascending dose with interleaved cohorts and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of YMI024 in healthy participants	Novartis Pharmaceuticals Corporation	$1,842	1
A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adult Participants	Regeneron Pharmaceuticals, Inc.	$1,360	2
A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AN	UCB SA	$1,063	1
A PHASE 1, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, SINGLE-ASCENDING DOSE STUDY OF LY3844583 IN HEALTHY PARTICIPANTS, AND MULTIPLE-DOSE STUDY OF LY3844583 IN HEALTHY PARTICIPANTS AND PATIENTS WITH ATOPIC DERMATITIS	Eli Lilly and Company	$1,062	1
A RANDOMIZED, PARTICIPANT AND INVESTIGATOR-BLINDED, PLACEBO-CONTROLLED FIRST-IN-HUMAN STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING DOSES OF NCJ424 IN HEALTHY ADULT PARTICIPANTS	Novartis Pharmaceuticals Corporation	$1,054	1
A first-in-human, randomized, participant- and investigator-blinded, placebo controlled, single and multiple ascending dose study to assess the safety, tolerability, and pharmacokinetics of XEP527 in healthy participants	Novartis Pharmaceuticals Corporation	$680.00	1

Medicare Billing by Year

Year	Procedures	Beneficiaries	Services	Submitted	Medicare Paid
2023	7	291	659	$129,789	$50,106
2022	4	171	410	$80,618	$30,442
2021	4	217	452	$68,366	$37,521
2020	6	283	594	$83,984	$46,846

Total Patients

962

Total Services

2,115

Medicare Billing

$164,915

Procedure Codes

All Medicare Procedures & Services

21 procedure records from CMS Medicare Utilization

HCPCS	Description	Setting	Year	Patients	Services	Charges	Medicare Paid	Ratio
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	Facility	2023	65	378	$60,278	$25,190	41.8%
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	Facility	2023	69	70	$27,931	$9,258	33.1%
99239	Hospital discharge day management, more than 30 minutes	Facility	2023	65	66	$15,702	$6,330	40.3%
99213	Established patient office or other outpatient visit, 20-29 minutes	Facility	2023	42	76	$10,854	$3,621	33.4%
99236	Initial hospital care with same-day admission and discharge with high level of medical decision making, per day, if using time, at least 85 minutes	Facility	2023	14	14	$6,293	$2,323	36.9%
99214	Established patient office or other outpatient visit, 30-39 minutes	Facility	2023	24	29	$6,070	$2,285	37.6%
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	Facility	2023	12	26	$2,661	$1,100	41.3%
99232	Follow-up hospital inpatient care per day, typically 25 minutes	Facility	2022	66	298	$45,255	$17,544	38.8%
99223	Initial hospital inpatient care per day, typically 70 minutes	Facility	2022	43	46	$19,464	$7,131	36.6%
99239	Hospital discharge day management, more than 30 minutes	Facility	2022	47	50	$11,291	$4,397	38.9%
99222	Initial hospital inpatient care per day, typically 50 minutes	Facility	2022	15	16	$4,608	$1,371	29.7%
99232	Subsequent hospital inpatient care, typically 25 minutes per day	Facility	2021	72	290	$32,190	$17,826	55.4%
99223	Initial hospital inpatient care, typically 70 minutes per day	Facility	2021	63	64	$19,968	$10,809	54.1%
99239	Hospital discharge day management, more than 30 minutes	Facility	2021	65	66	$11,088	$6,057	54.6%
99233	Subsequent hospital inpatient care, typically 35 minutes per day	Facility	2021	17	32	$5,120	$2,828	55.2%
99232	Subsequent hospital inpatient care, typically 25 minutes per day	Facility	2020	87	348	$38,628	$21,610	55.9%
99239	Hospital discharge day management, more than 30 minutes	Facility	2020	86	88	$14,784	$8,195	55.4%
99223	Initial hospital inpatient care, typically 70 minutes per day	Facility	2020	45	46	$14,352	$7,904	55.1%
99233	Subsequent hospital inpatient care, typically 35 minutes per day	Facility	2020	41	75	$12,000	$6,788	56.6%
99222	Initial hospital inpatient care, typically 50 minutes per day	Facility	2020	13	13	$2,756	$1,546	56.1%
99231	Subsequent hospital inpatient care, typically 15 minutes per day	Facility	2020	11	24	$1,464	$802.28	54.8%

About Dr. Joseph Dellinger, MD

Dr. Joseph Dellinger, MD is a Internal Medicine healthcare provider based in Pasadena, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2014. The National Provider Identifier (NPI) number assigned to this provider is 1740691377.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Dellinger, MD has received a total of $77,175 in payments from pharmaceutical and medical device companies, with $18,898 received in 2024. These payments were reported across 93 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($50,526).

As a Medicare-enrolled provider, Dellinger has provided services to 962 Medicare beneficiaries, totaling 2,115 services with total Medicare billing of $164,915. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.

16,000 Woodworking Plans

Step-by-step blueprints for any project. Beginner to expert.

Detailed schematics Cutting lists & materials Lifetime access — $67

★★★★★ 60-day guarantee

Get Instant Access

Practice Information

Specialty Internal Medicine
Location Pasadena, CA
Active Since 05/16/2014
Last Updated 06/24/2021
Taxonomy Code 207R00000X
Entity Type Individual
NPI Number 1740691377

Products in Payments

BIVV020 (Drug) $1,500
ELIQUIS (Drug) $381.75
Avance Nerve Graft (Device) $149.07
Aimovig (Biological) $117.92
SAMSCA (Drug) $114.40
COSENTYX (Biological) $112.80
TECENTRIQ (Biological) $96.86
Victoza (Drug) $16.67

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.